Ocular Therapeutix (NSDQ:OCUL) posted first-quarter results today that were wider than the consensus on Wall Street, missing the earnings consensus and beating on revenue.
The Bedford, Mass.-based company reported losses of -$17.1 million, or -45¢ per share, on sales of $492,000 for the three months ended March 31, widening its losses by 24.4% on sales growth of 44.7% compared with Q1 2018.
Losses per share were -45¢, 3¢ ahead of the consensus on Wall Street, where analysts were looking for sales of $430,000.
Get the full story on our sister site, Drug Delivery Business.